Thalagen is under clinical development by San Rocco Therapeutics and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase I drugs for Sickle Cell Disease have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Thalagen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Thalagen overview

Thalagen is under development for the treatment of beta-thalassemia and sickle cell disease. It is administered through the intravenous route. The therapeutic candidate comprises autologous CD34 positive hematopoietic progenitor cells transduced with TNS9.3.55, a lentiviral vector encoding the normal human beta-globin gene.

San Rocco Therapeutics overview

San Rocco Therapeutics (SRT) formerly known as Errant Gene Therapeutics is a healthcare solutions provider. The company develops treatments for life-threatening diseases. It offers therapies for the treatment of lou gehrig’s disease, huntington’s disease, cystic fibrosis, sickle cell anemia and thalassemia.SRT’s thalagen and CG-1521 products are developed for the treatment of the blood disorder thalassemia and refractory prostate cancer. The company’s CG-1521 is an inhibitor of histone deacetylase and represents a treatment paradigm for therapy resistant prostate cancer. It also develops pharmaceutical products for cancer and blood disorders. The company operates its offices in Chicago, Woodland Hills and New York, the US and operates subsidiary in Italy.SRT is headquartered in Chicago, Illinois, the US.

For a complete picture of Thalagen’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.